One Response to “The FDA and a Round World”

Comments

Read below or add a comment...

  1. Simon Bishop

    Dave, thanks for bringing this to the surface again, this is important. Ignoring the round world has contributed to the problems Pharma have always faced when aggregating and re-using data, and this has been a frustration of mine for my whole working life. Pharma and FDA have shared interests: to understand and interrogate data quickly and cheaply, whether for an individual study, an individual compound, a particular class of drug or broader.

    As you note, SDTM is not a complete solution to this problem. The solution to this is to utilise formal modelling of data from the point of study design. If a good model is employed, the context of the data can be made explicit in a way that computers can make use of the information.

    Here at GSK, and within the CDISC SHARE project, such a modelling approach is being employed. The model of clinical research that is being employed by both organisations is BRIDG. And this is being coupled with the use of a datatype standard (ISO21090). We have done enough work at GSK to feel comfortable that this approach will pay dividends. The BRIDG model, if implemented well, has enough capability to differentiate between activities being conducted because they were planned up front and activities that have been carried out due to being triggered by an “in-study” finding.

    Here is a link to two recent public presentations on SHARE:
    http://cdiscportal.digitalinfuzion.com/CDISC%20User%20Networks/Europe/English%20Language/Presentations/2011%2003%2022%20-%20TC%20CDISC%20SHARE/ESUG%20TC%20on%20SHARE%2022-Mar-2011%20-%20GSK%20Experience.pptx

    http://cdiscportal.digitalinfuzion.com/CDISC%20User%20Networks/Europe/English%20Language/Presentations/2011%2003%2022%20-%20TC%20CDISC%20SHARE/2011%2003%2022%20ESUG%20-%20Dave%20Iberson-Hurst%20slides.pdf

Leave A Comment...